Page 21 - Cautionary Note News Today

Nouveau Monde’s proprietary technology offers a greener and more sustainable alternative to that currently used in the traditional anode material production This technology is expected to be used in the Company’s Phase 1 purification facilities in Bécancour which are in the process of being commissioned Nouveau Monde’s Phase 1 purification facility is the first of its kind built in the Western World The same ...

Nouveau Monde Has Successfully Been Admitted and Will Commence Trading on the NYSE on Monday, May 24, 2021 Nouveau Monde Graphite Inc. is pleased to announce that it has received approval for the listing of its common shares on the New York Stock Exchange . The Company expects its common shares will open for trading on the NYSE on May 24, 2021, under the symbol “NMG”. “An extraordinary journey has just achieved another milestone. As Chairman, I am so proud of the Nouveau Monde team, and h...

Nouveau Monde Provides Clarification on a Prior News Release Nouveau Monde Graphite Inc. issued a press release on March 11, 2021 and filed a material change report on March 18, 2021 announcing the completion of a Front-End Loading engineering analysis for Phase 2 of its large-scale commercial lithium-ion anode material project in Bécancour, Québec . The Press Release and the MCR contained information extracted from the FEL-1 prepared by the Company and reviewed and … Nouveau Monde Graphite...

Syndax Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Clinical and Business Update - Today announced two of the prior responders from ongoing Phase 1 portion of AUGMENT-101 trial of SNDX-5613 achieved full count recovery bringing CR/CRh rate up to 23% - - Company on track to initiate pivotal Phase 2 portion of AUGMENT-101 trial in 2Q21 - - Enrollment of 23 cGVHD patients in Phase 2 expansion cohort testing axatilimab at 1 mg/kg complete; enrollment ongoing in pivotal ...

Share this article VANCOUVER, BC, April 29, 2021 /PRNewswire/ -  Augusta Gold Corp. (TSX: G) (OTCQB: AUGG) (FSE: 11B) ("Augusta Gold" or the "Company") is pleased to announce an update from its 2021 exploration program underway at its highly prospective wholly-owned Bullfrog Gold project located in Nevada, USA. The previously announced 2021 exploration program at the Bullfrog Gold Project (see news release dated February 11, 2021) has been underway with four drill rigs on-site. This news ...

Share this article Share this article WALTHAM, Mass., April 20, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced updated positive data from the Phase 1 dose escalation portion of the ongoing Phase 1/2 AUGMENT-101 trial of SNDX-5613 in patients with mixed lineage leukemia rearranged (MLLr) and nucleophosmin (NPM1c) mutant relapsed/re...

Share this article Share this article WALTHAM, Mass., April 15, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that it will host a conference call and live webcast to provide updated data from the Phase 1 dose escalation portion of the ongoing Phase 1/2 AUGMENT-101 trial of SNDX-5613 in patients with relapsed or refractory acute l...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Royalty Pharma Acquires OXLUMO™ Royalty Interest From Dicerna for up to $240 Million RP Management, LLCApril 8, 2021 GMT Dicerna to receive $180 million upfront and up to $60 million in potential additional milestone payments NEW YORK and LEXINGTON, Mass., April 08, 2021 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) (“Royalty Pharma”) and Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (“...

Syndax Announces Orphan Drug Designation Granted to Axatilimab for Treatment of Idiopathic Pulmonary Fibrosis News provided by Share this article Share this article WALTHAM, Mass., April 8, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to axatili...

Nouveau Monde’s mission and strategy is to become the Western World’s largest producer of high-quality anode materials to be used mainly in batteries for electrical vehicles and renewable energy storage Its large-scale lithium-ion active anode material facility in Bécancour, Québec is an integral part of its strategy Nouveau Monde has acquired a 200,000 m 2 parcel in the industrial park of Bécancour, adjacent ...